September 16, 2024

Supplementary File 1 from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study

Los puntos clave no están disponibles para este artículo en este momento.

Supplementary File 1 shows the Methods and Results for Part 1B

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Meric‐Bernstam et al. (Mon,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar